利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.035 秒)

    Methods for diagnosing prostatic adenocarcinoma
    1.
    发明授权
    Methods for diagnosing prostatic adenocarcinoma 失效
    诊断前列腺腺癌的方法

    公开(公告)号：US5710007A

    公开(公告)日：1998-01-20

    申请号：US536215

    申请日：1995-09-29

    申请人： Albert A. Luderer ,  Grant D. Carlson ,  Ya-Ting Chen ,  Thomas F. Soriano ,  Robert P. Thiel

    发明人： Albert A. Luderer ,  Grant D. Carlson ,  Ya-Ting Chen ,  Thomas F. Soriano ,  Robert P. Thiel

    IPC分类号： G01N33/53 ,  G01N33/573 ,  G01N33/574 ,  G01N33/537 ,  G01N33/542

    CPC分类号： G01N33/57488 ,  G01N33/57434

    摘要： The present invention relates to a method for diagnosing prostatic adenocarcinoma (CAP) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is less than about 7%, then the patient is diagnosed as having CAP. The present method can also be used on patients that have a total PSA of at least 10.1 ng/ml, but have also had a negative prostate biopsy.

    摘要翻译： 本发明涉及一种男性人类患者前列腺腺癌（CAP）诊断方法，无需进行活组织检查。 测量患者血液或血清中的总前列腺特异性抗原（PSA）水平。 如果患者的总PSA水平在2.5ng / ml和20.0ng / ml之间，则测量患者的血液或血清中的游离PSA水平。 计算游离PSA与总PSA的比例。 如果该比例小于约7％，那么患者被诊断为具有CAP。 本方法也可用于总PSA至少为10.1ng / ml，但也具有阴性前列腺活检的患者。